整理 | GLP1减重宝典内容团队处于临床阶段的生物技术公司Replicate Bioscience宣布,与诺和诺德达成长期战略合作,联合探索自我复制RNA(srRNA)在感染性疾病、免疫治疗及代谢类疾病中的应用潜力。合作的重点是结合诺和诺德在心脏代谢领域的研发与临床优势,与Replicate独特的srRNA平台共同开发创新候选药物,用于肥胖、2型糖尿病及相关慢性病。协议显示,双方将在部分心血管...
Source Link整理 | GLP1减重宝典内容团队处于临床阶段的生物技术公司Replicate Bioscience宣布,与诺和诺德达成长期战略合作,联合探索自我复制RNA(srRNA)在感染性疾病、免疫治疗及代谢类疾病中的应用潜力。合作的重点是结合诺和诺德在心脏代谢领域的研发与临床优势,与Replicate独特的srRNA平台共同开发创新候选药物,用于肥胖、2型糖尿病及相关慢性病。协议显示,双方将在部分心血管...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.